Why ProMIS Neurosciences, Inc.’s (PMN) Stock Is Down 5.55%
As of Thursday, September 03, ProMIS Neurosciences, Inc.’s PMN share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Commentary & Analysis
Why ProMIS Neurosciences, Inc.’s (PMN) Stock Is Up 5.66%
As of Tuesday, September 01, ProMIS Neurosciences, Inc.’s PMN share price has surged by 5.66%, which has investors questioning if this is right time to sell.Michael Rose
Why ProMIS Neurosciences, Inc.’s (PMN) Stock Is Down 6.18%
As of Wednesday, August 26, ProMIS Neurosciences, Inc.’s PMN share price has dipped by 6.18%, which has investors questioning if this is right time to buy.Michael Rose
Why ProMIS Neurosciences, Inc.’s (PMN) Stock Is Down 6.10%
As of Friday, July 31, ProMIS Neurosciences, Inc.’s PMN share price has dipped by 6.10%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ProMIS Neurosciences, Inc.’s (PMN) Stock Is Down 5.92%
As of Wednesday, July 29, ProMIS Neurosciences, Inc.’s PMN share price has dipped by 5.92%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PMN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $123.0 | $288.9 | 23% |
|
| Shares Out (Mil) | 9.1 | 54.0 | 19% |
|
| Institutional Ownership | 79.7% | 93.1% | 48% |
|
| Float (Mil) | 4.4 | 41.4 | 11% |
|
| Beta | -0.22 | 0.94 | 3% |
|
| Avg Daily Volume (000s) | 38 | 480 | 26% |
|
| Price Change (52-week) |
2.3% | 59.9% | 48% |
|
| Growth | PMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (55.3%) | (10.1%) | 6% |
|
| EPS (5yr) | 0.6% | 15.9% | 32 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (4.2%) | (15.6%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | na | na | |
| Current EPS | ($1.316) | na | na | |
| Month Ago EPS | ($1.538) | na | na | |
| # Rev Up | 2 | na | na | |
| # Rev Down | 0 | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | 2.6% | na | (83.9%) | |
| Financials | PMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($42) | ($43) | 17% |
|
| EPS (TTM) | ($8.451) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $80 | $190 | 19% |
|
| Valuation | PMN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.49 | 2.84 | 58% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PMN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (127.6%) | (47.7%) | 4% |
|
| ROE | (172.3%) | (55.0%) | 5% |
|
| Liabilities to Assets | 12.9% | 29.6% | 8% |
|
| F-Score | 3 | 3 | 18% |
|
ProMIS Neurosciences, Inc. did not pass any screens on 9/2/2026.
